Extending the Role of Antithrombotic Agents: An Example Based on the Low-Molecular-Weight Heparin, Tinzaparin

We illustrate a strategy for developing an antithrombotic agent based on the low-molecular-weight heparin (LMWH) tinzaparin experience. After anti-factor Xa and IIa activity pharmacokinetic characterization in healthy volunteers, clinical studies first explored the doses and then confirmed thrombosis prevention effects in postoperative (general and hip or knee replacement surgery) settings as compared with placebo and active treatments. This experience and additional dose-finding assessments led to large clinical studies verifying the effectiveness of tinzaparin in the treatment of deep vein thrombosis and acute pulmonary embolism. Subgroup analyses from these studies and preclinical experiments suggested a role for tinzaparin in patients with malignancy who are at high risk for thromboembolic complications.

Challenging patient populations and other thrombotic disorders spawned interest in tinzaparin studies in the obese, the hemodialysis, the stroke, peripheral angioplasty, and the pregnant patient as well as in children with thromboembolic disorders. New therapeutic challenges were addressed with a bridging study for patients requiring interruption of oral anticoagulant therapy, a study of patients undergoing cardioversion for atrial fibrillation, and outpatient venous thromboembolism treatment studies.

Efficient antithrombotic development programs not only build on traditional indications but elaborate on new therapeutic hypotheses generated from clinical studies, new therapeutic areas, and on-going basic science research programs.

Low-molecular-weight heparin - LMWH - heparin - tinzaparin - deep vein thrombosis - cancer - prophylaxis - pharmacokinetics

REFERENCES

• 1 Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga J M. Low-molecular-weight heparins: pharmacologic profile and product differentiation.  Am J Cardiol. 1998;  82 3L-10L
• 2 Linhardt R J, Gunay N S. Production and chemical processing of low molecular weight heparins.  Semin Thromb Hemost. 1999;  25(suppl 3) 5-16
• 3 Bozarth J, Larnkjaer A, Johansen K, Mousa S. Plasmatic versus vascular effects of low molecular weight heparin (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human endothelial cells. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12 2001 Paris; (abst 2056)
• 4 Mousa S A, Bozarth J M, Larnkjaer A, Johansen K. Vascular effects of heparin molecular weight fractions and low molecular weight heparins (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human endothelial cells.  Blood. 2000;  96 (11) 59b
• 5 Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.  Thromb Haemost. 1997;  77 317-322
• 6 Fossler M J, Barrett J S, Hainer J W et al.. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.  Am J Health System Pharm. 2001;  58 1614-1621
• 7 Innohep Package Insert .Boulder, CO; Pharmion Corporation 2002 June
• 8 Matzsch T, Bergqvist D, Hedner U, Østergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.  Thromb Haemost. 1987;  57 97-101
• 9 Pedersen P C, Østergaard P B, Hedner U, Bergqvist D, Matzsch T. Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers.  Thromb Res. 1991;  61 477-487
• 10 Barrett J S, Gibiansky E, Hull R D et al.. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis.  Int J Clin Pharmacol Ther. 2001;  39 431-446
• 11 Lassen M R, Borris L C, Christiansen H M et al.. Prevention of thromboembolism in 190 hip arthroplasties: comparison of LMW heparin and placebo.  Acta Orthop Scand. 1991;  62 33-38
• 12 Planes A, Samama M M, Lensing A WA et al.. Prevention of deep vein thrombosis after hip replacement comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin.  Thromb Haemost. 1999;  81 22-25
• 13 Hull R, Rasob G, Pineo G et al.. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.  N Engl J Med. 1993;  329 1370-1376
• 14 Matzsch T, Bergqvist D, Fredin H, Hedner U, Lindhagen A, Nistor L. Comparison of thromboprophylactic effect of a low molecular weight heparin versus dextran in total hip replacement.  Thromb Haemorrh Disord. 1991;  3 25-29
• 15 Lassen M R, Borris L C, Jensen H P et al.. Prevention of thromboembolic complications after total hip arthroplasty: comparison of two different dosage regimens of tinzaparin.  Thromb Haemost. 1995;  73 1104
• 16 Liezorovic A, Picolet H, Peyrieux J C, Boissel J P. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of logiparin and standard heparin.  Br J Surg. 1991;  78 412-416
• 17 Jorgensen L N, Lausen I, Rasmussen M S, Wille-Jorgensen P, Bergqvist D. Prolonged thromboprophylaxis with low molecular weight heparin (tinzaparin) following major general surgery: an individual patient data meta-analysis.  Blood. 2002;  100 (11) 501a
• 18 Marder V J, Soulen R L. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy.  J Lab Clin Med. 1977;  89 1018-1029
• 19 Breddin H K, Hach-Wunderle V, Nakov R, Kakkar V V. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.  N Engl J Med. 2001;  344 626-631
• 20 Siegbahn A, Hassan S Y, Boberg J et al.. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin: a dose finding study with LMWH-Novo.  Thromb Res. 1989;  55 767-778
• 21 Hull R D, Raskob G E, Pineo G F et al.. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med. 1992;  326 975-982
• 22 Green D, Hull R D, Brant R, Pineo G F. Low mortality in cancer patients treated with low molecular-weight versus standard heparin (letter).  Lancet. 1992;  339 1476
• 23 Valentine K A, Hull R D, Pineo G F. Low molecular-weight heparin therapy and mortality.  Semin Thromb Hemost. 1997;  23 173-178
• 24 Simonneau G, Sors H, Charbonnier B et al.. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  N Engl J Med. 1991;  337 663-669
• 25 The Columbus Investigators . Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med. 1997;  337 657-662
• 26 Koopmen M MW, Prandoni P, Piovella F et al.. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  N Engl J Med. 1996;  334 682-687
• 27 Levine M, Gent M, Hirsh J et al.. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med. 1996;  334 677-681
• 28 Hull R D, Pineo G F, Mah A F, Brant R F. Home-liteL safety and efficacy results for a study investigating the lone-term out of hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular-weight heparin versus warfarin. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12 2001 Paris; (abst OC1647)
• 29 Hainer J W, Barrett J S, Assaid C A et al.. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.  Thromb Haemost. 2002;  87 817-823
• 30 Hainer J W, Sherrard D J, Swan S K et al.. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.  Am J Kidney Dis. 2002;  40 531-538
• 31 Siguret V, Pautas E, Fevrier M et al.. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.  Thromb Haemost. 2000;  84 800-804
• 32 Smith M P, Norris L A, Stanley J L et al.. Innohep in pregnancy: a dose finding study of subcutaneous tinzaparin for thrombosis treatment and prevention during pregnancy.  Blood. 2000;  96 694A
• 33 Monagle P, Michelson A D, Bovill E, Andrew M. Antithrombotic therapy in children.  Chest. 2001;  119(suppl 1) 344S-370S
• 34 Barrett J S, Mitchell D J, Gastonguay M, Mitchell L, Andrew M. Forecasting anti-Xa activity in a pediatric dose finding trial with tinzaparin. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12 2001 Paris; (abst OC1647)
• 35 Kuhle S, Massicotte P, Andrew M et al.. A dose finding study of tinzaparin in pediatric patients.  Blood. 2002;  100 (11) 279a
• 36 Bath P MW, Lindenstrom E, Boysen G et al.. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.  Lancet. 2001;  358 702-710
• 37 Cohen M, Demers C, Gurfinkel E P et al.. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.  N Engl J Med. 1997;  337 447-452
• 38 Antman E M, McCabe C H, Gurfinkel E P et al.. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-q-wave myocardial infarction results of the Thrombolysis in Myocardial Infarction (TIMI)11B Trial.  Circulation. 1999;  100 1593-1601
• 39 Young J J, Kereiakes D J. Low-molecular-weight heparin in percutaneous coronary intervention: ready for prime time?.  ACC Curr J Rev. 2002;  11 (2) 59-64
• 40 Ornstein D L, Zacharski L R. The use of heparin for treating human malignancies.  Haemostasis. 1999;  29;(suppl 1) 48-60
• 41 Amirkhosravi A, Francis J, Mousa S. Anti-metastatic effect of low molecular weight heparin (LMWH) tinzaparin and tissue factor pathway inhibitor (TFPI). In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12 2001 Paris; (abst P1409)
• 42 Mousa S A, Mohamed S. Anti-angiogenic efficacy and mechanism of the low molecular weight heparin (LMWH), tinzaparin and tissue factor pathway inhibitor (TFPI): potential anti-cancer link and benefits. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12 2001 Paris; (abst P1981)
• 43 Mousa S A, Bozarth J, Hainer J W, Sprogel P, Johansen K, Barrett J S. Pharmacodynamic effects of tinzaparin following 175 IU/kg subcutaneous administration in healthy volunteers on plasma tissue factor pathway inhibitor (TFPI). In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12 2001 Paris; (abst P2299)
• 44 Chi Y W, Dentoni S, Deitcher S R. Superficial venous thrombosis and subsequent cancer. In: XVIII Congress of the International Society on Thrombosis and Haemostasis, July 6-12 2001 Paris; (abst P1514)
• 45 Mousa S A, Bozarth J M. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin.  Blood. 2002;  100 498a